2,2,2-trichloroethyl methylcarbamate | 28126-22-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,2,2-trichloroethyl methylcarbamate
• 英文别名: 2,2,2-Trichloraethyl-N-methylurethan；2,2,2-trichloroethyl N-methylcarbamate
• CAS: 28126-22-9
• 化学式: C₄H₆Cl₃NO₂
• 分子量: 206.456
• InChiKey: JSKPZVMPZAQBQB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  聚合甲醛 、 2,2,2-trichloroethyl methylcarbamate 、 sodium 4-methylbenzenesulfinate 在 甲酸 作用下， 生成 N-Methyl-N-p-toluolsulfonylmethylcarbaminsaeure-2,2,2-trichloraethylester
  参考文献：
  名称：

  van der Werf,S.; Engberts,J.B.F.N., Recueil des Travaux Chimiques des Pays-Bas, 1970, vol. 89, p. 423 - 441

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2,2-trichloroethoxycarbonyl azide 、 溶剂黄146 在 4-二甲氨基吡啶 、 copper diacetate 作用下， 以 乙腈 为溶剂， 反应 0.42h， 以99%的产率得到2,2,2-trichloroethyl methylcarbamate
  参考文献：
  名称：

  催化脱羧CN生成以生成烷基，烯基和芳基胺

  摘要：

  过渡金属催化的sp 2 C-N键形成是合成芳基胺的可靠方法。偶尔已经报道了催化sp 3 C-N的形成反应，并且相对未开发能够同时实现sp 2和sp 3 C-N形成的方法。在这里，我们通过催化脱羧CN的形成方法来解决这一挑战，该方法通过级联羧酸活化，酰基叠氮化物形成，Curtius重排和亲核加成反应进行。该反应使用天然丰富的有机羧酸作为碳源，容易制备的叠氮基甲酸作为氮源，以及4-二甲基氨基吡啶（DMAP）和Cu（OAc）2作为负载量低至0.1 mol％的催化剂，以气态N 2和CO 2为唯一副产物，可以高收率提供受保护的烷基，烯基和芳基胺。实例展示了天然产物和药物分子的后期功能化，有用的α-手性烷基胺的立体定向合成以及不同尿素和伯胺的快速构建。

  DOI：

  10.1002/anie.202010974

文献信息

• Substituted Amino-Pyrimidine Derivatives
  申请人：Endo Pharmaceuticals Inc.

  公开号：US20140038952A1

  公开（公告）日：2014-02-06

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药用可接受的盐、前药和溶剂化合物。还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物在共同调节PI3K和/或mTOR活性方面是有用的。通过这样做，这些化合物在治疗与PI3K/AKT/mTOR途径失调相关的疾病方面是有效的。有利的是，这些化合物作为双重PI3K/mTOR抑制剂发挥作用。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• AMIDE COMPOUND
  申请人：KORI Masakuni

  公开号：US20090163508A1

  公开（公告）日：2009-06-25

  An object of the present invention is to provide a novel fused-ring compound which has a FAAH inhibitory effect and is useful as an analgesic. The present invention relates to a compound represented by formula (I): wherein symbols are as defined in the specification, or salt thereof.

  本发明的一个目的是提供一种具有FAAH抑制作用并且作为镇痛药物有用的新型融环化合物。本发明涉及一种由下式表示的化合物： 其中符号如规范中定义的，或其盐。
• UREA DERIVATIVES AND THEIR THERAPEUTIC USE IN THE TREATMENT OF, INTER ALIA, DISEASES OF THE RESPIRATORY TRACT
  申请人：Woo Chi-Kit

  公开号：US20130143914A1

  公开（公告）日：2013-06-06

  Compounds of formula (I) are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory wherein R 1 is a radical of formula (IA) or (IB) or (IC): 10 Y is -0- or —S(0) p - wherein p is 0, 1 or 2; A is an optionally substituted cycloalkylene radical having 5, 6 or 7 ring atoms fused to a phenyl ring; and R 2 , R3b and R4b are as defined in the claims.

  式(I)的化合物是p38 MAPK抑制剂，在治疗呼吸系统疾病等炎症疾病中作为抗炎药物有用，其中R1是式(IA)或(IB)或(IC)的基团：Y是-0-或-S(0)p-，其中p为0、1或2；A是一个有5、6或7个环原子与苯环融合的可选择取代的环烷基基团；而R2、R3b和R4b如权利要求中所定义。
• METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF
  申请人：Academia Sinica

  公开号：US20170362265A1

  公开（公告）日：2017-12-21

  The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

  本公开涉及一种用于生成高甘霖、杂交和复合型N-糖的新型模块化方法。本公开还涉及到合成的N-糖阵列被点在涂有氧化铝的载玻片上。这些阵列可用于检测和分析合成的N-糖与糖结合分子（如HIV-1中和抗体）之间的结合相互作用。本公开还涉及一种用于识别与阵列上各种类型分子结合的试剂和定义阵列上结合到这些试剂的分子的结构元素的方法。本文提供的阵列和方法可用于一般抗原表位鉴定、药物发现以及作为分析工具。本公开还提供了有用的糖类和表位决定因子，可用于检测、诊断、复发监测和预防HIV等病理性疾病。
• TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE
  申请人：Finch Harry

  公开号：US20120088763A1

  公开（公告）日：2012-04-12

  Compounds of formula (I) are inhibitors of p38 MAP kinase, useful as anti-inflammatory agents in the treatment of inter alia, diseases of the respiratory tract wherein; R 1 is C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, phenyl which is optionally substituted, 5- or 6 membered monocyclic heteroaryl which is optionally substituted, or a radical of formula (II) wherein n is 1 or 2, and R 3 and R 4 are independently H or C 1 -C 6 alkyl, or R 3 and R 4 taken together with the nitrogen to which they are attached form a 6-membered heterocyclic ring optionally containing a further heteroatom selected from N and O; Y is —O— or —S(O) p — wherein p is 0, 1 or 2; A is an optionally substituted divalent arylene radical, or a mono- or bicyclic heteroarylene radical, or a C 3 -C 6 divalent cycloalkylene radical having 5 or 6 ring atoms, or a piperidinylene radical wherein the ring nitrogen is linked to R 2 NHC(═O)W—; W is a bond, —NH— or —C(R A )(R B ), wherein R A and R B are independently H, methyl, ethyl, amino, hydroxyl or halo; and R 2 is a radical as defined in the claims.

  化合物(I)的式子是抑制p38 MAP激酶的，可用于治疗呼吸道疾病等炎症疾病，其中：R1为C1-C6烷基，C3-C6环烷基，苯基（可选取代基），5-或6-成员单环杂芳基（可选取代基），或式子(II)中的基团，其中n为1或2，R3和R4独立地为H或C1-C6烷基，或R3和R4与它们连接的氮一起形成一个6-成员杂环环，该环可选地包含进一步的杂原子，所选自N和O；Y为—O—或—S(O)p—，其中p为0，1或2；A为可选取代的二价芳基基团，或单环或双环杂芳基基团，或具有5个或6个环原子的C3-C6二价环烷基基团，或哌啶基团，其中环氮连接到R2NHC(═O)W—；W为键，—NH—或—C(RA)(RB)，其中RA和RB独立地为H，甲基，乙基，氨基，羟基或卤素；而R2则为声明中所定义的基团。